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Abstract
Background: Public injecting of recreational drugs has been documented in a number of cities worldwide and was
a key risk factor in a HIV outbreak in Glasgow, Scotland during 2015. We investigated the characteristics and health
needs of people involved in this practice and explored stakeholder attitudes to new harm reduction interventions.
Methods: We used a tripartite health needs assessment framework, comprising epidemiological, comparative, and
corporate approaches. We undertook an analysis of local and national secondary data sources on drug use; a series
of rapid literature reviews; and an engagement exercise with people currently injecting in public places, people in
recovery from injecting drug use, and staff from relevant health and social services.
Results: Between 400 and 500 individuals are estimated to regularly inject in public places in Glasgow city centre:
most experience a combination of profound social vulnerabilities. Priority health needs comprise addictions care;
prevention and treatment of blood-borne viruses; other injecting-related infections and injuries; and overdose and
drug-related death. Among people with lived experience and staff from relevant health and social care services,
there was widespread – though not unanimous – support for the introduction of safer injecting facilities and
heroin-assisted treatment services.
Conclusions: The environment and context in which drug consumption occurs is a key determinant of harm, and
is inextricably linked to upstream social factors. Public injecting therefore requires a multifaceted response. Though
evidence-based interventions exist, their implementation internationally is variable: understanding the attitudes of
key stakeholders provides important insights into local facilitators and barriers. Following this study, Glasgow plans
to establish the world’s first co-located safer injecting facility and heroin-assisted treatment service.
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Background
Public injecting is commonly defined as the injecting of
recreational drugs in places accessible to the general pub-
lic, such as alleyways, public toilets, and stairwells [1, 2]. It
has been described in a number of cities worldwide, in-
cluding London, Baltimore, Vancouver, Sydney, and
Dublin [3–7], and has been identified as an important fac-
tor in an ongoing HIV outbreak among people who inject
drugs in Glasgow, Scotland’s largest city [8].
However, there is little up-to-date evidence as to the
characteristics or health needs of people who inject
drugs in public places, particularly outside North Amer-
ica or Australia.
Some cities affected by public injecting have intro-
duced safer injecting facilities and heroin-assisted treat-
ment as harm reduction measures [9–11]. Safer injecting
facilities (SIFs) are hygienic environments where illicit
drugs – purchased off the premises – can be consumed
under clinical supervision [10, 12]. Heroin-assisted treat-
ment (HAT) refers to the prescription of pharmaceutical
heroin (diamorphine) by medical professionals to treat
opiate-dependent individuals who do not benefit from
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existing substitution therapies, such as methadone or
buprenorphine [11, 13].
Both of these interventions have been recommended by
national and international bodies such as the UK Advisory
Council on the Misuse of Drugs and the European Moni-
toring Centre for Drugs and Drug Addiction [14–16], but
implementation to date has been limited. In the UK, for
instance, no safer injecting facility has ever operated and
HAT is not currently routinely available from addictions
services.
Understanding facilitators and barriers to implementa-
tion of these interventions is therefore important. How-
ever, few studies have examined this area. In particular,
attitudes of professional stakeholders from health, social
care, and law enforcement have not (to our knowledge)
previously been described.
This study aimed to investigate the characteristics and
health needs of people who inject drugs in public in
Glasgow, Scotland. It also examined factors relevant to
the implementation of safer injecting facilities and
heroin-assisted treatment, which are not currently pro-
vided anywhere in the UK.
Methods
We used an established tripartite framework for health
needs assessment [17], comprising the following strands:
Epidemiological assessment
We collated and analysed secondary data from a range
of local sources, including injecting equipment provision
(IEP) outlets, the city council Land and Environmental
Services (responsible for clearing drug-related litter) the
Scottish Ambulance Service, Community Safety Glas-
gow, and a drug-related deaths database. Due to space
constraints, only results from the first two of these are
presented in this article: details of these sources and
guidance on their interpretation are provided in Table 1.
Results from the other analyses are available from the
full report.
A series of rapid literature reviews were undertaken to
identify published research on the health needs of people
who inject drugs in public places and to evaluate the evi-
dence for the specific interventions of interest. Details of
search strategies and results are available online
(Additional file 1).
Comparative assessment
Information on services provided in other regions and
countries for people who inject drugs in public places was
gathered during the literature review (Additional file 1).
Performance data for local addictions services were col-
lated from a Scotland-wide surveillance study of people
who inject drugs [18], the national Drug and Alcohol
Treatment Waiting Times and Drug-Related Deaths
databases [19, 20], and local data on opioid substitution
therapy prescribing.
Corporate assessment
In order to understand stakeholder perspectives on pub-
lic injecting, a three-part engagement exercise was
undertaken as follows:
 Six semi-structured interviews with people who
inject drugs in the city centre, recruited through an
existing Assertive Outreach service;
 a focus group with 15 people in recovery from drug
use, recruited through a local peer network; and
 an online survey with 33 staff from relevant health
services, community services, support organisations,
and enforcement agencies.
The engagement exercise focused on three topics: the
health needs of people who inject drugs in public places;
experiences of current services; and attitudes to poten-
tial novel services. Question schedules are available in
the online Additional file 2. The interviews and focus
group were audio recorded and subsequently tran-
scribed. Results of the consultation were analysed using
the framework method with the support of an experi-
enced qualitative researcher.
Ethics, consent, and permissions
This project was undertaken as part of routine service
monitoring and quality improvement, so ethics committee
approval was not required [21]. All stakeholders who par-
ticipated in interviews and focus groups gave verbal in-
formed consent prior to participation. Verbal (rather than
written) consent was chosen given the nature of the pro-
ject as a routine quality improvement initiative, and for
practical reasons in the case of focus groups. Participant
consent was recorded in the transcripts of the interviews
and focus groups. For stakeholders who participated in
the online engagement exercise, the survey included an in-
formation page and contact details in case of any queries,
and participants were asked to select from a series of op-
tions as to their consent to participate and their willing-
ness to be directly quoted in any publications.
Results
Who is injecting in public?
Data from local services targeting people involved in
public injecting suggest that this population is predom-
inantly male, aged between 30 and 50 years, and of
Scottish ethnic origin (Table 2). The high rate of home-
lessness observed locally in this population was corrobo-
rated by published research showing that public
injecting is closely associated with a combination of so-
cial vulnerabilities, including homelessness and housing
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insecurity, offending, and destitution [1, 4, 22–25]. By
applying estimates of the prevalence of public injecting
in three UK cities to local IEP data, we estimated that
between 400 and 500 individuals may be injecting in
public places in Glasgow city centre on a regular basis
(Additional file 3).
Why – and where – is public injecting taking place?
Engagement with people currently injecting drugs and
those in recovery suggested that public injecting repre-
sents a complex trade-off between wanting to inject im-
mediately after acquiring drugs – because of withdrawal
symptoms and a fear of arrest or robbery – and feelings
of shame, and a wish not to be seen by the general pub-
lic. Lack of private space in which to inject was also a
key factor. These themes are consistent with previous
qualitative research among public injectors [2, 3, 26–29].
“I had to go down below a bridge to inject with other
using addicts, as a result of if I get caught doing it in
the [homeless] hostel, I would have been papped out.”
Focus group participant (in recovery).
Mapping reports of drug-related litter and incidents of
drug misuse indicated that public injecting in Glasgow is
concentrated in the south-east area of the city centre
(Fig. 1). These data and our stakeholder engagement
identified a range of public injecting sites, including
alleyways, car parks, stairwells, public toilets, and waste-
lands. The choice of location was largely dictated by the
geography of local drug markets and the desire for priv-
acy and shelter.
“There aren’t really any places to go. As you say, it’s
like public toilets or things like that you’re needing to
go to, and obviously you’re taking the chance of getting
caught.”
Interviewee (currently injecting drugs).
What are the health needs of people who inject in public
places?
People with lived experience of injecting drug use re-
ported that health was a low priority during periods of
active drug use, despite a high level of need. Participants
highlighted a number of reasons for this, including the
demands of their addiction, adverse social circum-
stances, fatalistic attitudes towards health, and fears of
potential repercussions or stigma when seeking help.
“[When asked about barriers to better health] Just this
life I’ve got just now. Terrible. Being homeless and all
that, running about the city centre, shoplifting,
begging, just doing anything to make money.”
Interviewee (currently injecting drugs).
Table 1 Data sources presented in epidemiological strand of needs assessment
Name Description Guidance on interpretation
Injecting Equipment Provision
(IEP) clients and transactions
Demographic and clinical details, and transaction
history, for individuals utilising IEP outlets in the
city centre. Based on data from the Neo database,
which covers all IEP services across NHS Greater
Glasgow and Clyde.
Data are limited to clients reporting injecting heroin
and/or cocaine, to exclude users of performance- and
image-enhancing drugs, who have a different
epidemiological profile and set of health needs. Pilot
analyses demonstrated that injecting of other drugs
(such as novel psychoactive substances) among city
centre IEP attendees was negligible. A degree of
duplication may exist within the Neo system, with
some individuals having registered on more than
one occasion. Data are therefore presented separately
for clients using any of the seven IEP outlets in the
city centre during 2015 those with ≥5 transactions
during 2015 (denoted ‘repeat clients’; a proxy for
unique users) those with ≥50 transactions during
2015 (denoted ‘high-frequency clients’) Since location
of use is not currently recorded in Neo, data are also
presented separately for clients accessing IEP via the
Assertive Outreach team: this is a service set up to
address the needs of public injectors and is therefore
the best proxy indicator for public injecting.
Drug-related litter Reports of drug-related litter made to Glasgow
City Council’s Land & Environmental Services
(LES) department
These data do not include information on volume
of litter (e.g. number of needles) or any clean-ups
undertaken on private property by individuals or
companies. They also rely on reporting by members
of the public. These data are therefore presented
to indicate the likely geographical distribution of
public injecting but will underestimate its extent.
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“To be honest, I’m just ravaged wi’ addiction and
when I’m ravaged I kind of cannae take care of
myself.”
Interviewee (currently injecting drugs).
Four key health needs were identified from our synthe-
sis of local data and the published literature, as follows.
Addictions care
The literature review found that public injecting is as-
sociated with a higher intensity of addiction, as indi-
cated by injecting frequency, number of bodily
injecting sites, poly-drug use, and validated measures of
dependency [10–12, 18]. Locally, 37% of individuals
known to the Assertive Outreach team reported current
structured addictions treatment, suggesting a sizeable
Table 2 Characteristics of people using city centre IEP outlets during 2015 who reported injecting heroin and/or cocaine
All clients (%) ‘Regular clients’ ≥5
transactions (%)
‘High frequency clients’
≥50 transactions (%)
Clients receiving IEP via
Assertive Outreacha (%)
Agegroupb
< 20 years 10 (0.3) 2 (0.2) 0 (0.0) 0 (0.0)
20–29 years 318 (9.6) 87 (8.5) 21 (14.9) 43 (14.5)
30–39 years 1423 (42.9) 444 (43.3) 54 (38.3) 132 (44.4)
40–49 years 1297 (39.1) 394 (38.4) 54 (38.3) 104 (35.0)
≥ 50 years 272 (8.2) 98 (9.6) 12 (8.5) 18 (6.1)
Gender
Male 2702 (81.4) 850 (82.9) 118 (83.7) 244 (82.2)
Female 618 (18.6) 175 (17.1) 23 (16.3) 53 (17.8)
Ethnicity
Scottish 3075 (92.6) 956 (93.3) 133 (94.3) 277 (93.9)
Other white ethnic groupc 181 (5.5) 48 (4.7) 7 (5.0) 14 (4.7)
Other ethnic groupd 41 (1.2) 14 (1.4) 1 (0.7) 1 (0.3)
Unknown 23 (0.7) 7 (0.7) 0 (0.0) 3 (1.0)
Last recorded housing statuse
Owner or renting 2448 (73.7) 697 (68.0) 79 (56.0) 121 (40.7)
Homeless 755 (22.7) 276 (26.9) 46 (32.6) 127 (42.8)
Roofless 114 (3.4) 52 (5.1) 16 (11.3) 46 (15.5)
Unknown 3 (0.1) 0 (0.0) 0 (0.0) 3 (1.0)
Primary drugs of injectionf
Heroin only 2682 (86.6) 826 (80.6) 113 (80.1) 237 (79.8)
Both heroin & cocaine 228 (6.9) 127 (12.4) 24 (17.0) 36 (12.1)
Cocaine only 187 (5.6) 34 (3.3) 1 (0.7) 3 (1.0)
Incomplete/unknowng 223 (6.7) 38 (3.7) 3 (2.1) 24 (8.1)
Last recorded treatment statush
In structured treatment 538 (16.2) 219 (22.9) 44 (32.4) 109 (36.7)
Not in structured treatment 716 (21.6) 308 (32.3) 50 (36.8) 133 (44.8)
Prefer not to say 1670 (50.3) 431 (45.0) 42 (30.9) 50 (16.8)
No answer 396 (11.9) 67 (7.0) 5 (3.7) 5 (1.7)
Total 3320 1025 141 297
aNote that this is a subset of the total number of clients (‘All clients’) and will include individuals from the ‘regular’ and ‘high frequency’ client groups. It is shown
separately to highlight the characteristics of this subset of IEP clients most likely to be involved in public injecting
bAs recorded at most recent transaction
cCensus codes 1B-1Z
d Census codes 2A, 3F-3Z, 4D-4Y, 5C-5Y, 6A-6Z
eAs recorded at most recent transaction. Homeless defined as living in temporary or unstable accommodation; roofless defined as rough sleeping
fIndividuals can have more than one primary drug of injection
gPrimary drug of injection is not a mandatory field so may be left incomplete, even if information on drugs used by that client is available from other fields
hAs recorded at most recent transaction. Structured treatment defined as tier 3 or 4 services (see reference [41])
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population for whom existing treatment options may
be failing to reduce street drug use (Table 2). Stake-
holder attitudes to local addictions care were generally
very favourable, but some staff identified challenges in
providing sufficiently intensive or flexible care for this
population and a need for a greater focus on harm
reduction.
Blood-borne virus risk
The literature review identified an association between
public injecting and: sharing injecting equipment; inject-
ing in larger groups; and inappropriate disposal of nee-
dles and syringes [3, 4, 7, 22–25, 30, 31]. A smaller
number of studies have suggested that public injecting is
also associated with higher prevalence of blood-borne vi-
ruses [23, 32]. Local data show that people known to city
centre IEP outlets tend to take fewer needles at each
transaction – a risk factor for sharing – and have much
lower rates of return of used needles for safe disposal,
compared to other IEP outlets in the area (Table 3).
Other injecting-related infections and injuries
Both the literature review and stakeholder feedback identi-
fied a link between public injecting and the risk of
injecting-related infections and injury: for instance, due to
disrupted hygiene routines, poor venous access in cold wea-
ther, and rushing to avoid detection [3, 6, 22, 27, 33, 34].
For instance, femoral vein (groin) injecting is often pre-
ferred for public injecting, as it is felt to be more
rapid and reliable: however, it carries a greater risk of
deep vein thrombosis, arterial puncture, and local or
systemic infection.
“You’re outside, you’re freezing, you’re desperate, you’re
in a hurry and you end up hitting an f***ing artery or
something, do you know what I mean?”
Focus group participant (in recovery).
“...you can get your groin easy, it’s in, out, two
seconds…but if you’re trying to get a wee vein in your
Fig. 1 Number of drug-related litter incidents in the city centre and surrounding areas during 2015
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arms and you’re needing to get warm and get tourneys
[tourniquets] on, you can’t do that kind of stuff in wee
limited spaces or places you’ve got limited time.”
Interviewee (currently injecting drugs).
Overdose and drug-related death
Our literature review identified an increased risk of over-
dose among people who inject drugs in public places
[22, 23, 33, 35, 36], linked to rushed injecting to avoid
detection or interruption [3, 25, 27]. Although current sur-
veillance systems in the UK do not include data on injecting
location, the demographic characteristics of people involved
in public injecting in Glasgow (as shown in Table 2) match
closely those most at risk of drug-related death [20].
Existing service provision
Existing services for people who inject drugs in Glasgow
span the four ‘tiers’ of addictions services described by
the UK National Treatment Agency [37], including 9
multi-disciplinary Community Addictions Teams; spe-
cialist addictions teams for clients who are female,
homeless or involved in the criminal justice system; ad-
diction liaison teams in all acute hospitals; and 68 inject-
ing equipment provision outlets. Local performance data
suggest that the quality of service provision in Glasgow
compares well to other areas of the UK and to inter-
national standards (Additional file 4).
Potential novel interventions: safer injecting facilities
Our engagement exercise found that stakeholders were
generally in favour of establishing a safer injecting facil-
ity in Glasgow, alluding to the evidence from other
countries and identifying specific local benefits in the
context of the HIV outbreak.
“It’s a safe environment you’re in. You’re not in your
close [stairwell], you’re not in a back alley where if
anything happens there’s nobody there.”
Interviewee (currently injecting drugs).
“It has got to quite a ridiculous stage where members
of the public, small businesses and communities are
asking “why can’t you give these people somewhere safe
to go and inject””
Senior staff, IEP services
However, some stakeholders cited concerns about le-
gality (since the operation of a SIF in the UK would
contravene the Misuse of Drugs Act 1971 as it currently
stands), public opinion, and operational risks.
“If there are waiting times to access the facility there is
no guarantee that the service user will use the facility
consistently...”
Senior staff, Community Safety Glasgow
“[It] should not be seen as a panacea but rather part
of a package of care to the most vulnerable
population.”
Advocacy and support organisation leader
Potential novel interventions: heroin-assisted treatment
Analysis of secondary data (Table 2) and engagement
responses suggested that a significant proportion of
those involved in public injecting in Glasgow city centre
may be eligible for – and benefit from – heroin-assisted
treatment. In our consultation, stakeholders generally
Table 3 Transactions at city centre IEP outlets during 2015 made by clients who reported injecting heroin and/or cocaine
All clients ‘Regular clients’ (≥5
transactions)
‘High frequency clients’ (≥50
transactions)
Clients of Assertive
Outreach team
Total number of transactions 31,298 27,526 13,735 2325
Equipment provided
All needles 262,480 189,752 69,365 12,778
Longer needles for deep vein injection 120,562
(45.9)
86,765 (45.7) 32,003 (46.1) 7827 (61.3)
Water 158,387 133,683 56,720 12,343
Average number of needles taken at each
transaction
8.4 6.9 5.1 5.5
Estimated number of needles returneda (%
of total)
70,756
(27.0)
47,488 (25.0) 3198 (4.6) 16 (0.1)
aRecorded by IEP staff based on client estimates
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welcomed the prospect of HAT in Glasgow, citing the
evidence for improved retention in addictions care and
greater social stability, as well as a reduced risk from
contaminated heroin. However, some raised concerns re-
garding cost and the potential for adverse public
opinion.
“I wish they would. Because you know something, it
takes the smack out the city. It takes the illegal stuff
out, and at least you know what you’re putting into
your body.”
Interviewee (currently injecting drugs)
“You can put as many posters up as you like, saying
that there is an increase in HIV in places. You need to
think about it differently. That’s where I think safe
injecting routes and injecting [prescribed] heroin…you
take away the chaos. Then you have a chance to work
on the attitude.”
Focus group participant (in recovery)
“Public perceptions of the programme may lead to
greater stigma and possibly reduced engagement”
Manager, addictions services
Recommendations
Based on these findings, we made seven recommendations
to address public injecting in Glasgow city centre:
1. Develop a strategy for cross-sectoral co-ordination
between different agencies involved with this
population, recognising the social determinants of
public injecting.
2. Support the development of a peer network for
harm reduction aimed at people in active drug use,
building on successful local peer-led recovery
initiatives.
3. Review models of delivery for specialist addiction
services to ensure they can meet the complex needs
of this population, with particular emphasis on
access, engagement, and harm reduction.
4. Maximise out-of-hours access to injecting equipment
through staffed outlets and peripatetic teams.
5. Introduce and evaluate a pilot safer injecting facility
in the city centre, through close partnership
working and integration with existing services.
6. Introduce and evaluate a pilot service for HAT for
people who continue to use street heroin despite
optimal opioid substitution therapy.
7. Incorporate questions on public injecting into
routine assessments in existing services and national
surveillance systems.
These recommendations have been endorsed by Glas-
gow City Alcohol and Drugs Partnership and work is
currently underway to progress their implementation.
Following an options appraisal, proposals are being de-
veloped by Glasgow City Health and Social Care Part-
nership to pilot the world’s first co-located safer
injecting facility and heroin-assisted treatment service.
This process will be described in more detail in a forth-
coming study.
Challenges to implementation of the recommendations
include: identification of a suitable location for the pro-
posed facility; community engagement and consultation;
and ensuring close integration with existing services.
Furthermore, although HAT can be delivered legally
within existing medicines legislation in the UK, the legal
status of a safer consumption facility is more complex.
At the time of writing, the Scottish Government has pe-
titioned the UK Government to amend the Misuse of
Drugs Act 1971, or to devolve drugs legislation to the
Scottish Parliament, in order to permit the operation of
such a facility: the UK Government has indicated it has
no intention of doing so.
Discussion
Main findings of this study
This study found that public injecting in Glasgow city
centre is prevalent and associated with significant health
harms. Though the health needs identified in this assess-
ment are universal among people who inject drugs, pub-
lic injecting adds an additional layer of complexity and
risk – both through the experience itself and through its
close association with adverse social circumstances such
as homelessness. Responses to public injecting must
therefore address its ‘upstream’ determinants as well as
mitigating the resultant harms. Among people with lived
experience and staff from relevant health and social care
services, there was widespread – though not unanimous
– support for the local implementation of new harm re-
duction interventions such as safer injecting facilities
and heroin-assisted treatment.
What is already known?
Public injecting has been reported in a number of cities
worldwide. Our findings corroborate previous research sug-
gesting that the environment and context in which drug
consumption occurs has profound implications for health,
and that public injecting is often a marker of deep social ex-
clusion [2, 26, 38]. Although evidence-based interventions
exist, the extent of implementation varies internationally.
For instance, at present no area in the UK provides safer
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injecting facilities or access to heroin-assisted treat-
ment programmes, despite recommendations from the
UK Advisory Council on the Misuse of Drugs, the
British Medical Association and the Faculty of Public
Health, and national clinical guidelines for the man-
agement of drug dependence [14, 39–41].
What this study adds
This is the first comprehensive profile of the demo-
graphic characteristics and health needs of people who
inject drugs in public places in the UK for more than
two decades [22]. We have also described for the first
time attitudes of professional stakeholders to the imple-
mentation of safer injecting facilities and heroin-assisted
treatment, interventions which have a strong evidence
base but remain politically sensitive. Our methods and
findings may be useful for colleagues elsewhere who
wish to understand the scale of public injecting, its asso-
ciated health harms, and how to implement relevant
interventions.
Limitations
Place of use is not recorded by any existing routine data
sources on drug-related harms in Scotland or the rest of
the UK. We therefore relied on proxy indicators for pub-
lic injecting, such as contact with an Assertive Outreach
service set up to meet the needs of this population.
Some of our data sources were designed for the purpose
of service delivery rather than surveillance or research:
we took a number of steps to maximise the validity of
these data, such as excluding individuals with < 5 trans-
actions per year from injecting equipment provision
data, and triangulating findings across multiple sources.
Conclusions
The environment and context in which drug consumption
occurs is a key determinant of harm, and is inextricably
linked to upstream social factors. Public injecting therefore
requires a multifaceted public health response. Though
evidence-based interventions to reduce public injecting and
related harms exist, their implementation is variable. Fol-
lowing this study, Glasgow plans to establish the world’s
first co-located safer injecting facility and heroin-assisted
treatment service; progress on implementation and the re-
sults of evaluation will be reported in due course.
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